| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Fabio Mitsuo Lima | Q58917260 |
| P2093 | author name string | Gabriela De Nardi Sanches-da-Silva | |
| Luiza Fonseca Sales Medeiros | |||
| P2860 | cites work | A guild of 45 CRISPR-associated (Cas) protein families and multiple CRISPR/Cas subtypes exist in prokaryotic genomes | Q21090166 |
| HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor | Q22242268 | ||
| CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes | Q24625361 | ||
| CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III | Q24628207 | ||
| A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity | Q24669850 | ||
| Off-target Effects in CRISPR/Cas9-mediated Genome Engineering | Q26859390 | ||
| Development and applications of CRISPR-Cas9 for genome engineering | Q28241526 | ||
| Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease | Q28284509 | ||
| Small CRISPR RNAs guide antiviral defense in prokaryotes | Q28290898 | ||
| CCR5 gene disruption via lentiviral vectors expressing Cas9 and single guided RNA renders cells resistant to HIV-1 infection | Q28542878 | ||
| CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1 | Q28646859 | ||
| Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene | Q29614892 | ||
| Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection | Q29614956 | ||
| Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation | Q29615068 | ||
| CRISPR interference limits horizontal gene transfer in staphylococci by targeting DNA | Q29615786 | ||
| Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements | Q29615788 | ||
| Identification of genes that are associated with DNA repeats in prokaryotes | Q29615790 | ||
| Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity | Q29615792 | ||
| DNA targeting specificity of RNA-guided Cas9 nucleases | Q29615793 | ||
| Inhibition of HIV-1 entry by extracts derived from traditional Chinese medicinal herbal plants | Q33490833 | ||
| Seamless modification of wild-type induced pluripotent stem cells to the natural CCR5Δ32 mutation confers resistance to HIV infection | Q33854184 | ||
| DNA interrogation by the CRISPR RNA-guided endonuclease Cas9. | Q33931841 | ||
| Inhibition of HIV-1 infection of primary CD4+ T-cells by gene editing of CCR5 using adenovirus-delivered CRISPR/Cas9. | Q38889625 | ||
| Genome editing of the HIV co-receptors CCR5 and CXCR4 by CRISPR-Cas9 protects CD4+ T cells from HIV-1 infection | Q40042102 | ||
| CRISPR/Cas9-Mediated CCR5 Ablation in Human Hematopoietic Stem/Progenitor Cells Confers HIV-1 Resistance In Vivo | Q40192805 | ||
| Excision of Latent HIV-1 from Infected Cells In Vivo: An Important Step Forward | Q40230137 | ||
| In Vivo Excision of HIV-1 Provirus by saCas9 and Multiplex Single-Guide RNAs in Animal Models | Q40263108 | ||
| Excision of HIV-1 DNA by gene editing: a proof-of-concept in vivo study | Q40668686 | ||
| Functional screening of guide RNAs targeting the regulatory and structural HIV-1 viral genome for a cure of AIDS. | Q40829178 | ||
| Use of the CRISPR/Cas9 system as an intracellular defense against HIV-1 infection in human cells | Q41265657 | ||
| Hot News: Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure | Q41919384 | ||
| Minimal 2'-O-methyl phosphorothioate linkage modification pattern of synthetic guide RNAs for increased stability and efficient CRISPR-Cas9 gene editing avoiding cellular toxicity. | Q47124138 | ||
| Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes | Q47585560 | ||
| Adaptation in the env gene of HIV-1 and evolutionary theories of disease progression | Q47872743 | ||
| Crossing enhanced and high fidelity SpCas9 nucleases to optimize specificity and cleavage. | Q48230762 | ||
| CCR5Δ32 in HCV infection, HCV/HIV co-infection, and HCV-related diseases | Q50166400 | ||
| Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects. | Q52422958 | ||
| Eugenics lurk in the shadow of CRISPR. | Q52423681 | ||
| Rapid and highly efficient mammalian cell engineering via Cas9 protein transfection. | Q52423691 | ||
| Genome scale screening identification of SaCas9/gRNAs for targeting HIV-1 provirus and suppression of HIV-1 infection. | Q52431359 | ||
| CRISPR/Cas9 inhibits multiple steps of HIV-1 infection. | Q52719897 | ||
| Biological significance of a family of regularly spaced repeats in the genomes of Archaea, Bacteria and mitochondria. | Q55033791 | ||
| HIV-1 inhibition in cells with CXCR4 mutant genome created by CRISPR-Cas9 and piggyBac recombinant technologies. | Q55190209 | ||
| Inducing CCR5Δ32/Δ32 Homozygotes in the Human Jurkat CD4+ Cell Line and Primary CD4+ Cells by CRISPR-Cas9 Genome-Editing Technology. | Q55280315 | ||
| Removal of HIV DNA by CRISPR from Patient Blood Engrafts in Humanized Mice. | Q55346907 | ||
| HIV infection | Q57096915 | ||
| Human CCR5Δ32 (rs333) polymorphism has no influence on severity and mortality of influenza A(H1N1)pdm09 infection in Brazilian patients from the post pandemic period | Q58584471 | ||
| Ten ways in which He Jiankui violated ethics | Q61783015 | ||
| Experiments that led to the first gene-edited babies: the ethical failings and the urgent need for better governance | Q61810171 | ||
| Chemokine receptors and HIV entry | Q74012124 | ||
| Development of antiretroviral drug resistance | Q84780613 | ||
| Prediction of off-target activities for the end-to-end design of CRISPR guide RNAs | Q89579863 | ||
| A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells | Q90788612 | ||
| HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation | Q92144268 | ||
| CRISPR elements in Yersinia pestis acquire new repeats by preferential uptake of bacteriophage DNA, and provide additional tools for evolutionary studies. | Q33985645 | ||
| RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection. | Q34025414 | ||
| Distinct functional sites for human immunodeficiency virus type 1 and stromal cell-derived factor 1alpha on CXCR4 transmembrane helical domains | Q34045610 | ||
| Long stretches of short tandem repeats are present in the largest replicons of the Archaea Haloferax mediterranei and Haloferax volcanii and could be involved in replicon partitioning | Q34057597 | ||
| The effect of genetic variation in chemokines and their receptors on HIV transmission and progression to AIDS. | Q34118844 | ||
| Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study | Q34126545 | ||
| Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells | Q34482784 | ||
| Generation of knock-in primary human T cells using Cas9 ribonucleoproteins. | Q34487189 | ||
| Human Germline CRISPR-Cas Modification: Toward a Regulatory Framework | Q34503980 | ||
| High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. | Q34507554 | ||
| Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus | Q34655645 | ||
| HIV infection: epidemiology, pathogenesis, treatment, and prevention | Q34662270 | ||
| The CRISPR/Cas9 system inactivates latent HIV-1 proviral DNA | Q35177829 | ||
| CCR5: From Natural Resistance to a New Anti-HIV Strategy | Q35260605 | ||
| Rapid characterization of CRISPR-Cas9 protospacer adjacent motif sequence elements | Q35846582 | ||
| BLT humanized mice as a small animal model of HIV infection | Q35998374 | ||
| Antiretroviral drugs: critical issues and recent advances | Q36020992 | ||
| Evaluation of off-target and on-target scoring algorithms and integration into the guide RNA selection tool CRISPOR. | Q36068445 | ||
| Predictors of human immunodeficiency virus (HIV) infection in primary care: a systematic review protocol | Q36137693 | ||
| Current status of gene therapy strategies to treat HIV/AIDS. | Q36143446 | ||
| Genome editing of CXCR4 by CRISPR/cas9 confers cells resistant to HIV-1 infection. | Q36181852 | ||
| HIV transmission | Q36526615 | ||
| CXCR4-CCR5: a couple modulating T cell functions | Q36786977 | ||
| Human Immunodeficiency Virus (HIV). | Q37045832 | ||
| Negative Feedback Regulation of HIV-1 by Gene Editing Strategy | Q37177251 | ||
| High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity | Q37196274 | ||
| Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases. | Q37420333 | ||
| Current tests to evaluate HIV-1 coreceptor tropism | Q37429745 | ||
| Rapid and tunable method to temporally control gene editing based on conditional Cas9 stabilization | Q37661378 | ||
| HIV virology and pathogenetic mechanisms of infection: a brief overview | Q37720350 | ||
| HIV-1 assembly, release and maturation. | Q38539565 | ||
| A combinational CRISPR/Cas9 gene-editing approach can halt HIV replication and prevent viral escape. | Q38759997 | ||
| CRISPR/Cas9-Derived Mutations Both Inhibit HIV-1 Replication and Accelerate Viral Escape. | Q38779072 | ||
| CRISPR-Cas9 Can Inhibit HIV-1 Replication but NHEJ Repair Facilitates Virus Escape | Q38800708 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | CRISPR | Q412563 |
| P304 | page(s) | 8458263 | |
| P577 | publication date | 2019-08-21 | |
| P1433 | published in | International Journal of Genomics | Q26842357 |
| P1476 | title | The Potential Use of the CRISPR-Cas System for HIV-1 Gene Therapy | |
| P478 | volume | 2019 |
Search more.